Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers. There has been much advancement in the treatment of HR+/HER2 negative metastatic breast cancer (MBC), in particular the development of more tail...

Descripción completa

Detalles Bibliográficos
Autores principales: Armaghani, Avan J, Han, Hyo Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680678/
https://www.ncbi.nlm.nih.gov/pubmed/33239910
http://dx.doi.org/10.2147/BCTT.S219436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680678/
https://www.ncbi.nlm.nih.gov/pubmed/33239910
http://dx.doi.org/10.2147/BCTT.S219436

Ejemplares similares